title: Alternating versus sequential therapy in advanced breast cancer.
authors.forename: A
authors.initials: A
authors.lastname: Romero
authors.forename: M G
authors.initials: MG
authors.lastname: Rabinovich
authors.forename: J E
authors.initials: JE
authors.lastname: Pérez
authors.forename: M
authors.initials: M
authors.lastname: Macchiavelli
authors.forename: B A
authors.initials: BA
authors.lastname: Leone
authors.forename: E
authors.initials: E
authors.lastname: Strauss
authors.forename: D
authors.initials: D
authors.lastname: Goldar
authors.forename: L A
authors.initials: LA
authors.lastname: Alvarez
authors.forename: C
authors.initials: C
authors.lastname: Vallejo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate